Josep M Llovet

发表

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

J. Llovet, S. Wilhelm, Lila Adnane, 2008, Molecular Cancer Therapeutics.

Design and endpoints of clinical trials in hepatocellular carcinoma.

Riccardo Lencioni, Barnett S Kramer, Jayant Talwalkar, 2008, Journal of the National Cancer Institute.

Staging systems in hepatocellular carcinoma.

Fernando Pons, J. Llovet, M. Varela, 2005, HPB : the official journal of the International Hepato Pancreato Biliary Association.

Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma

Riccardo Lencioni, R. Lencioni, J. Llovet, 2010, Seminars in liver disease.

Gene expression in fixed tissues and outcome in hepatocellular carcinoma.

Kenji Ikeda, Derek Y. Chiang, Goro Watanabe, 2008, The New England journal of medicine.

Hepatocellular carcinoma

A. Burroughs, J. Bruix, J. Llovet, 2003, The Lancet.

The Barcelona approach: Diagnosis, staging, and treatment of hepatocellular carcinoma

Josep Fuster, J. Bruix, J. Llovet, 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

Obesity, inflammatory signaling, and hepatocellular carcinoma-an enlarging link.

S. Friedman, J. Llovet, S. Toffanin, 2010, Cancer cell.

Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets

Jessica Zucman-Rossi, Michael R Stratton, Sandrine Imbeaud, 2015, Nature Genetics.

Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma.

Arthur Liberzon, Masahiro Kobayashi, Yujin Hoshida, 2011, Gastroenterology.

Resection and Liver Transplantation for Hepatocellular Carcinoma

V. Mazzaferro, J. Llovet, M. Schwartz, 2005, Seminars in liver disease.

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

Masatoshi Kudo, Osamu Yokosuka, Gianluca Masi, 2017, The Lancet.

Sorafenib in advanced hepatocellular carcinoma.

Dieter Häussinger, Sergio Ricci, Armando Santoro, 2008, The New England journal of medicine.

Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy.

J. Llovet, A. Forner, A. Villanueva, 2010, Annual review of medicine.

Molecular Pathogenesis and Targeted Therapies for Intrahepatic Cholangiocarcinoma

V. Mazzaferro, J. Llovet, N. Bardeesy, 2015, Clinical Cancer Research.

Hepatitis B virus and hepatocellular carcinoma.

J. Bruix, J. Llovet, Jordi Bruix, 2003, Journal of hepatology.

Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial

Ramon Planas, Carmen Ayuso, J. Bruix, 2002, The Lancet.

Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model

Llorenç Quintó, Xavier Forns, J. Llovet, 2002, Hepatology.

Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps

J. Llovet, A. Villanueva, S. Toffanin, 2008, Current opinion in oncology.